Renaissance Technologies’s Galmed Pharmaceuticals GLMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-282
Closed -$16K 4216
2022
Q3
$16K Buy
282
+106
+60% +$9.04K ﹤0.01% 3918
2022
Q2
$21K Buy
+176
New +$29.2K ﹤0.01% 4111
2021
Q2
Sell
-337
Closed -$208K 3574
2021
Q1
$208K Sell
337
-306
-48% -$212K ﹤0.01% 3137
2020
Q4
$360K Buy
643
+453
+238% +$283K ﹤0.01% 2970
2020
Q3
$121K Sell
190
-243
-56% -$198K ﹤0.01% 3184
2020
Q2
$373K Buy
433
+210
+94% +$177K ﹤0.01% 2969
2020
Q1
$139K Sell
223
-138
-38% -$131K ﹤0.01% 3170
2019
Q4
$375K Buy
361
+269
+292% +$231K ﹤0.01% 2998
2019
Q3
$79K Sell
92
-87
-49% -$87.3K ﹤0.01% 3290
2019
Q2
$237K Sell
179
-3
-2% -$3.87K ﹤0.01% 3261
2019
Q1
$268K Sell
182
-5
-3% -$7.27K ﹤0.01% 3130
2018
Q4
$229K Buy
+187
New +$327K ﹤0.01% 3101
2018
Q2
Sell
-498
Closed -$500K 3369
2018
Q1
$500K Buy
498
+289
+138% +$421K ﹤0.01% 2915
2017
Q4
$345K Buy
+209
New +$309K ﹤0.01% 2982
2016
Q3
Sell
-61
Closed -$49K 3386
2016
Q2
$49K Buy
+61
New +$57.7K ﹤0.01% 3234
2015
Q3
Sell
-60
Closed -$109K 3230
2015
Q2
$109K Sell
60
-34
-36% -$59.1K ﹤0.01% 3078
2015
Q1
$159K Buy
+94
New +$141K ﹤0.01% 2936

Other funds holding GLMD

Renaissance Technologies's GLMD Position: Q4 2022 in Review

Renaissance Technologies sold out of Galmed Pharmaceuticals (GLMD) in Q4 2022, closing a stake of 282 shares — an estimated $16K sold.

Renaissance Technologies first reported a position in GLMD in Q1 2015 and held it in 17 quarters. The position peaked at $500K in Q1 2018. 22 funds tracked by Wall St. Rank hold GLMD as of Q4 2022.

  • Renaissance Technologies reported no remaining Galmed Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Renaissance Technologies sold 282 Galmed Pharmaceuticals shares in Q4 2022, an estimated $16K.
  • Renaissance Technologies first reported a position in Galmed Pharmaceuticals in Q1 2015 and held it in 17 quarters.
  • Renaissance Technologies's Galmed Pharmaceuticals position peaked at $500K in Q1 2018.
  • 22 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2022.

Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.